Clinical and Laboratory Characteristics of 42 Patients With Phospholipid-Dependent Inhibitors of Coagulation Classified According to Their Coagulation Profile
. | Coagulation Profile . | P . | |
---|---|---|---|
dRVVT (n = 24) (%) . | KCT (n = 18) (%) . | ||
Age (yrs) | |||
Mean ± SD | 41.5 ± 12.8 | 47.5 ± 16.8 | NS |
Median; range | 39; 19-70 | 43; 20-76 | |
Sex | |||
M/F | 8/16 | 0/18 | .0065 |
Anti–β2-GPI antibodies | |||
Cardiolipin in solid-phase | 24 (100) | 13 (72) | .0059 |
Mean ± SD (GPL and/or MPL units) | 122 ± 61 | 46 ± 52 | .0001 |
β2-GPI in solid-phase | 16 (67) | 7 (39) | NS |
Associated diseases | 12 (50) | 10 (56) | NS |
SLE/SLE-like | 5 | 4 | |
Other autoimmune disorders | 4 | 2 | |
Other diseases | 3 | 4 | |
Thrombosis | 17 (71) | 4 (22) | .0018 |
Venous | 13 | 2 | .004 |
Arterial | 4 | 2 | |
Recurrent abortions (≥2) | 6 (25) | 5 (28) | NS |
Thrombocytopenia | 2 (8) | 5 (28) | NS |
. | Coagulation Profile . | P . | |
---|---|---|---|
dRVVT (n = 24) (%) . | KCT (n = 18) (%) . | ||
Age (yrs) | |||
Mean ± SD | 41.5 ± 12.8 | 47.5 ± 16.8 | NS |
Median; range | 39; 19-70 | 43; 20-76 | |
Sex | |||
M/F | 8/16 | 0/18 | .0065 |
Anti–β2-GPI antibodies | |||
Cardiolipin in solid-phase | 24 (100) | 13 (72) | .0059 |
Mean ± SD (GPL and/or MPL units) | 122 ± 61 | 46 ± 52 | .0001 |
β2-GPI in solid-phase | 16 (67) | 7 (39) | NS |
Associated diseases | 12 (50) | 10 (56) | NS |
SLE/SLE-like | 5 | 4 | |
Other autoimmune disorders | 4 | 2 | |
Other diseases | 3 | 4 | |
Thrombosis | 17 (71) | 4 (22) | .0018 |
Venous | 13 | 2 | .004 |
Arterial | 4 | 2 | |
Recurrent abortions (≥2) | 6 (25) | 5 (28) | NS |
Thrombocytopenia | 2 (8) | 5 (28) | NS |
Abbreviation: NS, not significant.